The role of intravenous vasodilators in acute heart failure management

Eur J Heart Fail. 2014 Aug;16(8):827-34. doi: 10.1002/ejhf.123.

Abstract

Acute heart failure is a major cause of emergency hospital admission, with significant impact on health resources and patient outcomes. With no new treatments for over 20 years, the advent of new innovative therapies may facilitate a radical change in our approach to such patients. In this article, we examine the current evidence for the use of current intravenous vasodilators in AHF management, and review the potential of novel therapies currently in development.

Keywords: Acute heart failure; Nitrates; Vasodilators.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acute Disease
  • Administration, Intravenous
  • Atrial Natriuretic Factor / therapeutic use
  • Benzoates / therapeutic use
  • Heart Failure / drug therapy*
  • Humans
  • Natriuretic Agents / therapeutic use*
  • Natriuretic Peptide, Brain / therapeutic use
  • Natriuretic Peptides / therapeutic use
  • Nitrates / therapeutic use*
  • Peptide Fragments / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Relaxin / therapeutic use
  • Snake Venoms / therapeutic use
  • Vasodilator Agents / therapeutic use*

Substances

  • Benzoates
  • Natriuretic Agents
  • Natriuretic Peptides
  • Nitrates
  • Peptide Fragments
  • Recombinant Proteins
  • Snake Venoms
  • Vasodilator Agents
  • serelaxin protein, human
  • Natriuretic Peptide, Brain
  • BAY 58-2667
  • Ularitide
  • Atrial Natriuretic Factor
  • Relaxin
  • cenderitide